Symptomatic Support for Diarrhea and Digestive Strain

The medication is considered relevant for easing symptoms related to physical discomfort across a range of gastrointestinal conditions, primarily those associated with systemic imbalance. The medicine is commonly used across domains where short-term symptom management is appropriate, and generally provides support that helps ease the overall symptom burden.

It is relevant for easing symptoms that create noticeable functional strain during conditions associated with acute or disruptive episodes, such as diarrhea, and plays a role in managing symptoms related to antibiotic-associated diarrhea and traveler's diarrhea. This assistance is applied in addressing symptoms in clinical settings where supportive symptom management is appropriate.

“Applied in contexts where additional symptomatic support is needed, this medicine helps address symptom clusters that may become intense or disruptive.”

By providing this symptomatic assistance, it contributes to improved day-to-day comfort during symptomatic periods and may assist with maintaining functional stability during symptomatic phases, particularly when symptoms intensify or fluctuate.

---

Quick Fact: Used in situations involving symptoms related to physical discomfort during acute episodes and periods of systemic imbalance.

Regulatory References

1. Product information from Health Canada

Who Can and Cannot Use Энтерол? - Official Regulatory Information

The eligibility profile for Энтерол (Saccharomyces boulardii CNCM I-745) is defined by official regulatory documents, focusing on patient safety and the product's classification as a live yeast.

Contraindications and Prohibited Use

Use of this medicine is absolutely contraindicated for specific high-risk patient populations due to the confirmed risk of fungaemia (systemic fungal infection). These prohibited groups include:

• Immunocompromised patients (individuals with severely weakened immune systems).
• Critically ill patients.
• Patients with a Central Venous Catheter (CVC).
• Individuals with known hypersensitivity to Saccharomyces boulardii or product excipients, including those with Hereditary Fructose Intolerance (HFI).

---

Restricted and Conditional Use

Population	Regulatory Eligibility Status
Pregnancy	Not Recommended; preferable to avoid (due to insufficient reliable data).
Lactation/Breastfeeding	Not Recommended; preferable to avoid (due to insufficient reliable data).
Preterm Infants (under 1000g)	Caution Advised (insufficient reliable information).

Use is generally permitted in otherwise healthy adults and children under standard labeled conditions. Patients with specific sugar intolerances should consult a physician due to the presence of excipients in some formulations.

Interactions with other medicines and products

The interaction profile of Энтерол (Saccharomyces boulardii CNCM I-745) is highly specific and is primarily defined by a pharmacodynamic constraint involving co-administered antifungal treatments. As the active ingredient is a live yeast, regulatory information highlights a necessary caution regarding medicinal products active against fungi.

---

Official Interaction Statements

Category	Documented Finding	Outcome
Interacting Drug Class	Antifungal Agents (systemic or oral)	Pharmacodynamic Antagonism
Interaction Effect	Reduction of product efficacy	Loss of activity against the live yeast

---

Interaction Context and Scope

Official regulatory documents state that co-administration with antifungal medicinal products may result in a reduction in the product's intended efficacy due to this antagonistic effect. This applies to antifungals administered orally or systemically. The interaction is classified as clinically significant because it compromises the core function of the product.

Since Saccharomyces boulardii CNCM I-745 is a non-systemic agent that acts locally within the gut, regulatory labeling does not document any interactions involving human CYP450 metabolic enzymes or drug transporters (such as P-gp). Consequently, the product does not have documented interactions that alter the plasma levels of most co-administered systemic drugs.

The action of Энтерол (Saccharomyces boulardii CNCM I-745) is exclusively non-systemic and involves a complex, multi-targeted mechanism focused on modulating the dynamics of the gastrointestinal lumen at the cellular and molecular level.

Anti-Toxic and Anti-Secretory Modulation

The yeast employs a dual mechanism that directly limits the impact of pathogenic toxins. It secretes a protease that enzymatically degrades bacterial exotoxins (like C. difficile Toxins A/B), and simultaneously acts as a modulator to suppress the toxin-induced over-activation of cellular secretory pathways (such as the Adenylate Cyclase cascade). This combined action mediates a core physiological consequence: a net reduction of water and electrolyte secretion into the gut lumen.

---

Trophic Support and Epithelial Barrier Repair

The active ingredient functions as a trophic agent, stimulating the production of local factors like Polyamines (Spermidine and Spermine) which accelerate the proliferation and repair of intestinal cells. This mechanism influences the maintenance of the physical integrity of the gut lining by preserving the complex proteins known as Tight Junctions. The resulting physiological effect is a decrease in paracellular permeability, which supports the mucosal barrier function.

---

Competitive Exclusion and Local Immune Pathway Dampening

The yeast physically interacts with pathogenic microbes through co-aggregation and competitive exclusion, actively limiting the ability of harmful organisms to adhere to the mucosa. Furthermore, yeast-derived signals act as inhibitors of key local inflammatory pathways, particularly the NF-kappaB and MAPK cascades, thereby resulting in the downregulation of mucosal inflammation and an adjustment of the local micro-environment dynamics.

The administration of Энтерол (lyophilized Saccharomyces boulardii CNCM I-745) is based on established procedural guidelines. The sole approved route of administration is oral, typically using the 250 mg capsule or powder-for-suspension dosage form. Standard regimens establish a daily dose of 500 mg, achieved by taking one 250 mg unit twice daily, although dosing may be increased up to 1000 mg per day for certain labeled uses. The total duration of use is typically a short-term course ranging from one to three weeks.

Preparation and Administration Constraints

The medicine may be administered with or without food. For proper use, the active ingredient must not be exposed to temperature extremes or alcohol. The powder or capsule contents must not be mixed with hot liquids (exceeding 50 C), iced liquids, or alcoholic beverages, as these conditions compromise the viability of the living yeast cells.

Population-Specific and Procedural Rules

Administration to young children requires special consideration: the hard capsules are not to be swallowed by children under six years old due to the risk of aspiration; the powder/sachet form is the mandated alternative for this age group. Furthermore, strict procedural precautions apply in clinical settings: the product must not be opened near patients with a Central Venous Catheter (CVC), and healthcare providers must maintain rigorous hand hygiene to prevent accidental fungal contamination.

Research evidence / Overview of studies for Энтерол

This section summarizes the official research evidence describing the medicine’s clinical evaluation, as reported in authoritative governmental or peer-reviewed scientific sources. This overview describes what the research has studied, what findings have been observed, and what remains uncertain, without providing any clinical guidance or treatment recommendations.

---

Evidence for Preventing Diarrhea Associated with Antibiotics (AAD)

Research on diarrhea that was associated with taking antibiotics (AAD) involves multiple large Randomized Controlled Trials (RCTs) and subsequent extensive Meta-Analyses. These studies have explored whether patterns related to symptom stability during antibiotic use were monitored. The key outcome measured was the overall incidence (risk) of developing AAD, focusing on outcomes related to physical discomfort.

Analysis of the combined data describes findings where the risk of AAD was noted to be lower in patient groups where the active ingredient was administered, compared to control groups. Research reports describe the observed patterns as having a moderate degree of reproducibility across different study settings.

What remains uncertain is how these findings apply across the entire range of existing antibiotics, as research notes variability in the specific antibiotic classes studied. Additionally, long-term outcomes regarding the sustained stability of gut function beyond the immediate post-treatment period are not fully established.

---

Evidence for Managing Acute Diarrhea and Gastroenteritis

Clinical research has utilized short-term RCTs and systematic reviews exploring short-term symptom changes in the acute setting. These studies were designed to measure changes in the overall duration of the diarrhea episode and patterns in stool frequency/consistency in both children and adults.

Analysis of the pooled data describes patterns where the duration of diarrhea was recorded as shorter in cohorts where the ingredient was administered, compared to control groups. Findings described changes measured in stool consistency and frequency during the first few days of intervention. A key uncertainty noted is the heterogeneity (wide variability) in the underlying causes of acute diarrhea, which limits the findings to broader diagnostic categories.

---

Documented Research Gaps and Uncertainties

Scientific reviews acknowledge that the evidence quality varies across studies, and subgroup findings are uncertain for specific conditions, such as preventing C. difficile-associated diarrhea (CDD) recurrence in adults. Data for certain groups remain insufficient, especially for highly vulnerable or complex patient populations. Furthermore, comparative evidence is lacking in many instances, as most trials compare the product against a placebo. The research is ongoing to further explore and clarify the patterns observed in clinical settings.

Common questions about Энтерол (FAQ)

---

Q: How quickly does Enterol start working?

Clinical research has examined patterns of change in symptoms during treatment. Specifically, observational data from research suggests a reduction in the duration of the condition and changes in stool frequency may be noted within the first 48 hours of treatment initiation. This information is based on patterns observed in clinical trials reported in official sources.

---

Q: What time of day is best to take Enterol?

Official administration instructions do not specify a preferred time of day for taking the medicine. Regulatory information states that the product is typically taken once or twice daily. It may be administered either with or without food. The product’s official prescribing information indicates that timing relative to meals does not compromise its intended action.

---

Q: Is there research confirming Enterol's effectiveness against rotavirus?

While rotavirus is not always cited as a specific indication on regulatory labels, clinical reviews have examined the ingredient’s role in managing viral gastroenteritis in children. These meta-analyses describe observed patterns consistent with its use alongside other care for acute diarrhea, which often covers infections caused by viruses like rotavirus.

---

Q: Can Enterol be used to treat traveler's diarrhea?

According to regulatory documentation in certain countries, the medicine is explicitly indicated for the treatment and prevention of traveler's diarrhea. This classification is based on evidence reviewed by government health authorities regarding the product's function.

---

Q: How long can I take Enterol without consulting a doctor?

The therapeutic course defined in regulatory regimens is generally short-term. The product’s official warnings state that if diarrhea symptoms persist for more than two days despite being used according to the usual dosage, a reassessment of the condition is often noted as appropriate.

---

Q: Is there official data on Enterol overdose?

Official regulatory documents addressing safety and adverse events classify overdose information for this medicine as 'Not applicable.' This classification indicates that typical concerns associated with drug overdose are not formally documented in the product's prescribing information.

---

Q: Is there a difference in effectiveness between manufacturers of Enterol?

Regulatory documents refer only to the specific strain: Saccharomyces boulardii CNCM I-745, which is the sole active ingredient. Official guidance and documented effectiveness data are based strictly on studies of this specific, authenticated strain. This focus on the specific biological identity is relevant to its classification as a medicinal product.

---

Q: Does Enterol contain sugar or other sweeteners?

Yes, official regulatory documents list specific excipients (inactive ingredients) found in the formulations. Some versions, particularly the powder sachets, may contain sugars such as lactose and fructose. The presence of fructose is noted because the medicine is contraindicated for use in patients with Hereditary Fructose Intolerance (HFI).

Official Storage Requirements

To ensure the stability and viability of the active ingredient (Saccharomyces boulardii CNCM I-745), official labeling mandates specific environmental controls. The medicine must be stored at a temperature not exceeding 25 C (77 F). It is essential to keep the product in its original packaging in a dry, dark place to protect it from moisture and light degradation.

Handling and Safety

For safety, this medicine must always be stored out of the sight and reach of children. When preparing the medicine, it is restricted from being mixed with liquids or food that are excessively hot (specifically, over 50 C), iced, or contain alcohol, as this will compromise the live culture. There is also a specific handling precaution advising against opening capsules near patients with central venous catheters.

Disposal Guidelines

Disposal of any unused or expired product must follow local pharmaceutical regulations. It is prohibited to discard the medicine via household waste or wastewater (flushing down the toilet or sink); instead, it should be returned to an authorized collection facility or pharmacy for proper environmental disposal.